Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Management of Stable Vitiligo
Description
Doctor Rebecca Vasquez from UT Southwestern discusses the management of stable vitiligo, emphasizing the significance of treatment adherence for successful outcomes. She shares two cases: the first involved a 50-year-old male who exhibited significant improvement from 90% with consistent narrow band UVB and ruxolitinib therapy, highlighting the psychosocial impacts of the disease. Stable vitiligo is characterized by no new lesions or growth, typically defined as stable after six months to a year. Continuous treatment is vital to prevent relapse, which can occur in up to 40% of cases in the first year without therapy. The second case features a 10-year-old boy treated with narrow band UVB and clobetasol, who showed marked improvement after surgical therapy for stable vitiligo. Vasquez stresses the importance of shared decision-making, tailored to the patient's clinical presentation and individual goals, whether maintaining stability or pursuing repigmentation. She indicates that newer surgical approaches, such as autologous skin cell suspension, have increased repigmentation rates but require ongoing phototherapy. Overall, effective management integrates psychological support, stable maintenance therapy, and surgical options when appropriate, with an emphasis on patient involvement in treatment decisions.
View moreConclusions
- Maintaining effective treatment is essential to prevent relapse of stable vitiligo, as up to 40% may experience relapse within the first year after stopping treatment.
- Bi-weekly application of 0.1% tacrolimus ointment can significantly reduce relapse rates to 10%.
- Ruxolitinib has shown promising results, with over half of patients maintaining facial repigmentation for six months after stopping treatment.
- Patients should be involved in shared decision-making for their treatment approaches, aligning therapy with individual goals and psychosocial needs.
- Surgical options, including punch grafting and autologous skin cell suspension, are viable for stable vitiligo and can result in significant repigmentation.
- Ongoing phototherapy is essential for both maintaining improvements post-treatment and supporting the effectiveness of other interventions.
- 1. Sahni K, Parsad D. Stability in Vitiligo: Is there a Perfect Way to Predict it ?. J Cutan Aesthet Surg. 2013;6(2):75-82.
- 2. van Geel N, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023;37(11):2173-2184.
- 1. Cavalié M, Ezzedine K, Fontas E, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015;135(4):970-974.
- Harris JE, Pandya AG, Lebwohl M, Hamzavi IH, Grimes P, Gottlieb AB, Sofen HL, Moore AY, Wang M, Kornacki D, Butler K, Rosmarin D. Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years. Skin Health Dis. 2024 Aug 7;4(6):e404.
- Seneschal J, Speeckaert R, Taïeb A, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023;37(11):2185-2195.
- Hamzavi IH, Ganesan AK, Mahmoud BH, et al. Effective and durable repigmentation for stable vitiligo: a randomized within-subject controlled trial assessing treatment with autologous skin cell suspension transplantation. J Am Acad Dermatol. Published online August 23, 2024.